Stryker (SYK) Stock
Global medical device maker for surgery and implants. Here's the price, business snapshot, and what's worth knowing about Stryker in August 2026.
Stryker Corporation (SYK) is a global medical‑technology company best known for orthopaedics, surgical equipment, neurotechnology and patient-handling systems. Investors should know it sells high-margin implants, powered surgical tools and capital equipment to hospitals and clinics, giving it exposure to both recurring consumable sales and larger, cyclical procedure volumes. Growth drivers include an ageing population, innovation in implants and minimally invasive procedures, geographic expansion and selective acquisitions. Key considerations are sensitivity to elective-surgery cycles, hospital capital spending and regulatory approvals; reimbursement policies and competition from other device makers can also affect results. Stryker has a track record of reinvesting in R&D, pursuing M&A and returning cash to shareholders, but margins and growth rates can vary over time. This is general, educational information only — not personal investment advice. Values can rise and fall and past performance is not a reliable guide. Suitability depends on your circumstances; consider seeking regulated financial advice before investing.
Why It’s Moving
SYK stays on investors’ radar as analysts keep a positive stance despite softer target revisions.
- Analyst sentiment remains broadly constructive, with most covering firms still clustered around Buy or Moderate Buy ratings, suggesting Street confidence in Stryker’s long-term earnings power rather than a near-term reset in the story.
- Recent target cuts have trimmed some upside expectations, but ratings have largely stayed positive, indicating analysts are adjusting valuation assumptions more than turning negative on the business.
- The consensus range still implies meaningful upside versus the current share price, which can help keep investor attention on execution, margins, and demand trends in Stryker’s core medical-technology markets.
SYK stays on investors’ radar as analysts keep a positive stance despite softer target revisions.
- Analyst sentiment remains broadly constructive, with most covering firms still clustered around Buy or Moderate Buy ratings, suggesting Street confidence in Stryker’s long-term earnings power rather than a near-term reset in the story.
- Recent target cuts have trimmed some upside expectations, but ratings have largely stayed positive, indicating analysts are adjusting valuation assumptions more than turning negative on the business.
- The consensus range still implies meaningful upside versus the current share price, which can help keep investor attention on execution, margins, and demand trends in Stryker’s core medical-technology markets.
When is the next earnings date for STRYKER CORP (SYK)?
The next earnings date for SYK is July 30, 2026 based on the company’s historical reporting pattern. The report is expected to cover Q2 2026. Stryker has not always formally confirmed the date in advance, so this should be treated as the current estimated timing.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Stryker's stock with a target price of $389.27, indicating significant growth potential.
Financial Health
Stryker Corp shows strong revenue and profit margins, indicating solid financial performance overall.
Dividend
Stryker Corp's low dividend yield of 0.98% suggests limited returns from dividends. If you invested $1000 you would be paid $9.80 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring SYK
Regulatory Relief Stocks | FTC Court Ruling Impact
A federal appeals court has overturned an FTC order against Intuit, significantly limiting the agency's ability to use internal judges. This precedent forces regulators to face higher burdens of proof in federal court, providing potential relief to corporations fighting administrative overreach.
Published: 21 March 2026
Explore BasketGlobal Medtech UAE Healthcare Investment Basket 2025
The United Arab Emirates is making significant investments to upgrade its medical infrastructure, aiming to become a global healthcare destination. This basket provides exposure to the international US and EU-listed companies in pharmaceuticals, medtech, and digital health that supply this ambitious national project.
Published: 12 November 2025
Explore BasketHealthcare Innovation Brazil Investment Theme 2025
Brazil is ramping up investment to enhance its healthcare quality and access, creating significant opportunities for innovation. This basket offers exposure to key US and EU-listed companies providing the medical devices, software, and biotech research driving this transformation.
Published: 30 October 2025
Explore BasketMedTech Stocks: Brazil Market Risks & Opportunities
Brazil's growing demand for advanced healthcare presents an opportunity to modernize its medical infrastructure and improve patient outcomes. This basket offers exposure to the leading US and European companies supplying Brazil with robotic surgery systems, AI diagnostics, and innovative medical devices.
Published: 21 October 2025
Explore BasketHealthcare Titans: Brazil Growth vs Currency Volatility
Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.
Published: 14 October 2025
Explore BasketHealthcare Innovation: MedTech Giants Portfolio 2025
Growing demand for advanced healthcare in Africa highlights the global companies at the forefront of medical technology innovation. This theme offers exposure to US and EU-listed industry leaders in robotic surgery, diagnostic imaging, and other medical devices.
Published: 22 September 2025
Explore BasketWhy You’ll Want to Watch This Stock
Elective Surgery Exposure
Stryker benefits from demand for joint replacements and minimally invasive procedures, though revenues can move with surgical volumes and economic cycles.
Innovation and M&A
Regular new-product launches and selective acquisitions can extend market share, but integration and regulatory approval carry execution risk.
Global Footprint
Diversified geographic presence helps growth and resilience, though it brings exposure to local reimbursement policies and currency fluctuations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
